Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

The transaction is expected to close in the third quarter subject to fulfillment of customary closing conditions, including receipt of required regulatory approvals and 3SBio shar ...

Pfizer's complaint is that GSK and a Quebec, Canada-based subsidiary ID Biomedical are causing "commercial uncertainty" for its own RSV vaccine programme with the three patents, which Pfizer says ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

A new FDA framework for Covid-19 vaccines created confusion among physicians about what it means for young children ...

The Economic Affairs Committee launched an inquiry to investigate the impact of ageing on the UK economy and society, and the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

May 14, 2025 Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now Biotech ... May 9, 2025 Infant hospitalizations from RSV dropped after shots became available, US data shows ...

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.